Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mechanistic Models: Compartment Models in Individual and Population Analysis01:23

Mechanistic Models: Compartment Models in Individual and Population Analysis

288
Mechanistic models are utilized in individual analysis using single-source data, but imperfections arise due to data collection errors, preventing perfect prediction of observed data. The mathematical equation involves known values (Xi), observed concentrations (Ci), measurement errors (εi), model parameters (ϕj), and the related function (ƒi) for i number of values. Different least-squares metrics quantify differences between predicted and observed values. The ordinary least...
288
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

392
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
392

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Asymptotic online FWER control for dependent test statistics.

Statistical methods in medical research·2026
Same author

A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection.

The Journal of antimicrobial chemotherapy·2026
Same author

Hearing Impairments in People With Intellectual Disabilities: A Prospective Cohort Study on Prevalence and Healthcare Utilization.

Deutsches Arzteblatt international·2026
Same author

Effectiveness of an online interval group therapy for children with developmental language disorders: protocol for a randomised controlled intervention study.

BMJ open·2026
Same author

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study.

Clinical pharmacology and therapeutics·2026
Same author

Paired and AB/BA Cross-Over Design in Early Phase Clinical Trials: A Closer Look at Within-Subject Variance Bias.

Pharmaceutical statistics·2026

Related Experiment Video

Updated: Feb 20, 2026

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

8.1K

Model selection based on combined penalties for biomarker identification.

Eleni Vradi1, Werner Brannath2, Thomas Jaki3

  • 1a Department of Research and Clinical Sciences Statistics , Bayer AG , Berlin , Germany.

Journal of Biopharmaceutical Statistics
|October 27, 2017
PubMed
Summary

This study introduces a new stepwise method for selecting actionable biomarkers, creating simpler models for targeted medicine. The approach effectively identifies key features, improving model parsimony without sacrificing prediction accuracy.

Keywords:
Biomarker panelscombined penaltiesmodel selectionpenalized regressionregularizationsparsitystepwise variable selectiontreatment responder

More Related Videos

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

16.4K

Related Experiment Videos

Last Updated: Feb 20, 2026

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

8.1K
Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

16.4K

Area of Science:

  • Biostatistics
  • Bioinformatics
  • Computational Biology

Background:

  • Targeted medicine relies on actionable biomarkers for patient stratification.
  • Current biomarker selection methods often yield complex panels, hindering practical application.
  • Regularization methods using L0 and L1 norms face computational challenges in high-dimensional data.

Purpose of the Study:

  • To develop a more parsimonious biomarker selection method for high-dimensional data.
  • To address the limitations of existing non-convex, non-smooth regularization techniques.
  • To improve the practical utility of biomarker panels in classification tasks.

Main Methods:

  • Proposed a stepwise forward variable selection method.
  • Combined L0 norm with L1 or L2 norms for penalized likelihood criterion.
  • Applied the method to high-dimensional datasets.

Main Results:

  • The proposed method yields more parsimonious models by selecting fewer, relevant features.
  • Achieved comparable prediction performance to existing selection methods.
  • Demonstrated effectiveness through simulation studies and a real-world application.

Conclusions:

  • The stepwise L0-L1/L2 norm approach offers a computationally feasible and effective alternative for biomarker selection.
  • This method results in simplified biomarker panels suitable for targeted medicine.
  • Enhances the development of actionable biomarkers in high-dimensional settings.